AUSTIN, Texas, March 13 /PRNewswire-FirstCall/ -- Luminex Corporation introduces two new key products -- xPONENT, a new, more intuitive software interface which simplifies the user experience, and MagPlex microspheres, which add a magnetic component to the company’s core xMAP microsphere technology, enabling use on automation equipment. xPONENT and MagPlex will enhance both ease-of-use and automation capabilities expanding xMAP functionality in the company’s core market segments
Luminex’s xPONENT Software was developed with experts in human factors and ergonomic design. Customer-centric development and extensive field testing with customers has resulted in a user experience which is a significant step forward in the market place. The software suite incorporates over 300 new features all designed to simplify laboratory workflow and increase productivity. New features include enhanced security (21 CFR Part 11 compliance and electronic signatures), integration capabilities that allow users to transmit and receive data from Laboratory Information Systems (LIS/LIMS), integration with the most popular automated sample preparation systems, the ability to run magnetic bead applications and touch-screen capability.
xPONENT will be sold on new Luminex systems and will be available as an upgrade to the over 4100 existing Luminex 100 and 200 systems in the marketplace.
Luminex’s MagPlex Microspheres feature super-paramagnetic properties that make them ideal for running automated xMAP-based assays. These microspheres can be moved or held in place by a magnetic field. Many automated sample preparation systems utilize magnetic properties to automate the sample preparation steps in an assay. Automating sample testing using MagPlex microspheres on a robotic sample preparation system will minimize hands-on technician time, improve precision, and streamline workflow.
Gregory J. Gosch, vice president of marketing and sales at Luminex, said, “Ease-of-use and automation are very important product criteria for customers in our targeted market segments, particularly those in high-volume testing laboratories. We believe the automation capabilities offered by our MagPlex microspheres and the intuitive design of our xPONENT software are significant advances in automation and ease-of-use for both Luminex and multiplexing technologies in general.”
Luminex’s xMAP multiplexing technology allows researchers to perform numerous tests simultaneously for detection of gene sequences, protein interactions and other biological reactions, which are read in a compact analyzer. xMAP provides significant efficiencies versus traditional methods which require performing one test at a time.
About Luminex
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Luminex’s xMAP technology received the 2005 Clinical Diagnostics Technology of the Year Award from Frost & Sullivan. The Company was named in the 2005 Deloitte Fast 500 of fastest-growing technology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at www.luminexcorp.com.
Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company’s revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company’s strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward- looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Corporate Contact: Harriss T. Currie Vice President, Finance and Chief Financial Officer 512-219-8020 hcurrie@luminexcorp.com Media Contact: Nicole L. Cottrill Seigenthaler Public Relations 615-327-7999 ncottrill@seig-pr.com
Luminex Corporation
CONTACT: Corporate, Harriss T. Currie, Vice President, Finance and ChiefFinancial Officer of Luminex Corporation, +1-512-219-8020, orhcurrie@luminexcorp.com; or Media, Nicole L. Cottrill of SeigenthalerPublic Relations, +1-615-327-7999, or ncottrill@seig-pr.com, for LuminexCorporation
Web site: http://www.luminexcorp.com/
